{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:04:31Z","timestamp":1789430671934,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Next Generation EU - Mission 4 Component 2 Investment 1.4"},{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GMR23T2177"],"award-info":[{"award-number":["GMR23T2177"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union \u2013 NextGenerationEU \u2013 M4, C2, I1.1"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Among\n                      <jats:italic>F8<\/jats:italic>\n                      mutation types, main determinants of inhibitor development after replacement therapy in Hemophilia A (HA), nonsense mutations display wide variation in the associated risk. Translational readthrough (Rdthr) at premature termination codons (PTCs) produces traces of full-length factor VIII (FVIII) including missense and wild-type molecules (WT Rdthr), and may influence the immune response involved in inhibitor formation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      For inhibitor association analysis, we investigated\n                      <jats:italic>F8<\/jats:italic>\n                      genotypes, inhibitor status and Rdthr features in 335 PTCs (1048 patients), recorded in the European Association for Haemophilia and Allied Disorders (EAHAD) database, and exploited expression of\n                      <jats:italic>F8<\/jats:italic>\n                      PTCs variants. Mean-differences in affinity of HLA-DR alleles for FVIII WT peptides and their missense counterparts were bioinformatically calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      WT Rdthr was higher for patients affected by PTCs not associated with inhibitor and was not predicted at all in patients with PTCs detected in at least three inhibitor positive cases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009136,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001). WT Rdthr was lower for PTCs in the inhibitor prone FVIII light chain.\n                    <\/jats:p>\n                    <jats:p>Among FVIII PTCs fused with luciferase, quantitative output of WT Rdthr negative and positive groups did not differ, potentially highlighting for the positive group the importance of WT Rdthr to decrease inhibitor association. Readthrough output was the lowest among WT Rdthr negative PTCs, highly associated with inhibitors.<\/jats:p>\n                    <jats:p>\n                      The WT Rdthr prediction was extended to all PTCs that could arise by single nucleotide variations for the entire\n                      <jats:italic>F8<\/jats:italic>\n                      coding sequence. Estimated WT Rdthr was higher in PTCs reported in EAHAD than those predicted (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009662), foreseeing a higher risk of developing inhibitors.\n                    <\/jats:p>\n                    <jats:p>\n                      In silico mean differences in affinity of HLA-DR alleles for WT FVIII peptides and their missense counterparts, potentially arising from Rdthr of PTCs without WT formation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009297), were higher for missense variants predicted in patients with inhibitors than without (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and increased for PTCs present in more than one patient with inhibitor, potentially supporting immunogenic features.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The new genetic classification of HA PTCs may improve our knowledge about their relationship with inhibitors. It deserves to be explored for estimating inhibitor PTC association in HLA genotyped patients as well as in other human diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-026-01536-y","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:58:13Z","timestamp":1782712693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenic implications of translational readthrough modulate the association of F8 nonsense mutations with inhibitors in Hemophilia A"],"prefix":"10.1186","volume":"32","author":[{"given":"Maria Francesca","family":"Testa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Pinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Branchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Balestra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"1536_CR1","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/gim.2015.6","volume":"17","author":"KL Berrier","year":"2015","unstructured":"Berrier KL, Kazi ZB, Prater SN, Bali DS, Goldstein J, Stefanescu MC, et al. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med. 2015;17:912\u20138. https:\/\/doi.org\/10.1038\/gim.2015.6.","journal-title":"Genet Med"},{"key":"1536_CR2","doi-asserted-by":"publisher","first-page":"10061","DOI":"10.1093\/nar\/gku663","volume":"42","author":"S Blanchet","year":"2014","unstructured":"Blanchet S, Cornu D, Argentini M, Namy O. New insights into the incorporation of natural suppressor tRNAs at stop codons in Saccharomyces cerevisiae. Nucleic Acids Res. 2014;42:10061\u201372. https:\/\/doi.org\/10.1093\/nar\/gku663.","journal-title":"Nucleic Acids Res"},{"key":"1536_CR3","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1111\/jth.13443","volume":"14","author":"A Branchini","year":"2016","unstructured":"Branchini A, Ferrarese M, Lombardi S, Mari R, Bernardi F, Pinotti M. Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency. J Thromb Haemost. 2016;14:1994\u20132000. https:\/\/doi.org\/10.1111\/jth.13443.","journal-title":"J Thromb Haemost"},{"key":"1536_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1046\/j.1538-7836.2003.00013.x","volume":"1","author":"D David","year":"2003","unstructured":"David D, Santos IMA, Johnson K, Tuddenham EGD, McVey JH. Analysis of the consequences of premature termination codons within factor VIII coding sequences. J Thromb Haemost. 2003;1:139\u201346. https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00013.x.","journal-title":"J Thromb Haemost"},{"key":"1536_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/gim.2016.70","volume":"19","author":"JM de Vries","year":"2017","unstructured":"de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SCA, Stok M, et al. Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genet Med. 2017;19:90\u20137. https:\/\/doi.org\/10.1038\/gim.2016.70.","journal-title":"Genet Med"},{"key":"1536_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/humu.22981","volume":"37","author":"JT den Dunnen","year":"2016","unstructured":"den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 Update. Hum Mutat. 2016;37:564\u20139. https:\/\/doi.org\/10.1002\/humu.22981.","journal-title":"Hum Mutat"},{"key":"1536_CR7","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","volume":"122","author":"CL Eckhardt","year":"2013","unstructured":"Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122:1954\u201362. https:\/\/doi.org\/10.1182\/blood-2013-02-483263.","journal-title":"Blood"},{"key":"1536_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","volume":"339","author":"S Ehrenforth","year":"1992","unstructured":"Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, G\u00fcng\u00f6r T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594\u20138. https:\/\/doi.org\/10.1016\/0140-6736(92)90874-3.","journal-title":"Lancet"},{"key":"1536_CR9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/humu.23404","volume":"39","author":"M Ferrarese","year":"2018","unstructured":"Ferrarese M, Testa MF, Balestra D, Bernardi F, Pinotti M, Branchini A. Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B. Hum Mutat. 2018;39:702\u20138. https:\/\/doi.org\/10.1002\/humu.23404.","journal-title":"Hum Mutat"},{"key":"1536_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.omtm.2019.02.007","volume":"13","author":"A Ghosh","year":"2019","unstructured":"Ghosh A, Liao A, O\u2019Leary C, Mercer J, Tylee K, Goenka A, et al. Strategies for the induction of immune tolerance to enzyme replacement therapy in Mucopolysaccharidosis type I. Mol Ther Methods Clin Dev. 2019;13:321\u201333. https:\/\/doi.org\/10.1016\/j.omtm.2019.02.007.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1536_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1538-7836.2011.04191.x","volume":"9","author":"AC Goodeve","year":"2011","unstructured":"Goodeve AC, Reitsma PH, McVey JH, Working Group on Nomenclature of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Nomenclature of genetic variants in hemostasis. J Thromb Haemost. 2011;9:852\u20135. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04191.x.","journal-title":"J Thromb Haemost."},{"key":"1536_CR12","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","volume":"119","author":"SC Gouw","year":"2012","unstructured":"Gouw SC, Van Den Berg HM, Oldenburg J, Astermark J, De Groot PG, Margaglione M, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119:2922\u201334. https:\/\/doi.org\/10.1182\/blood-2011-09-379453.","journal-title":"Blood"},{"key":"1536_CR13","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","volume":"121","author":"SC Gouw","year":"2013","unstructured":"Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121:4046\u201355. https:\/\/doi.org\/10.1182\/blood-2012-09-457036.","journal-title":"Blood."},{"key":"1536_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00251-011-0513-0","volume":"63","author":"J Greenbaum","year":"2011","unstructured":"Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics. 2011;63:325\u201335. https:\/\/doi.org\/10.1007\/s00251-011-0513-0.","journal-title":"Immunogenetics"},{"key":"1536_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3324\/haematol.2018.195669","volume":"104","author":"DP Hart","year":"2018","unstructured":"Hart DP, Uzun N, Skelton S, Kakoschke A, Househam J, Moss DS, et al. Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A. Haematologica. 2018;104:599\u2013608. https:\/\/doi.org\/10.3324\/haematol.2018.195669.","journal-title":"Haematologica"},{"key":"1536_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01498","author":"DP Hart","year":"2020","unstructured":"Hart DP. FVIII immunogenicity\u2014bioinformatic approaches to evaluate inhibitor risk in non-severe hemophilia A. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.01498.","journal-title":"Front Immunol"},{"key":"1536_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/hae.12566","volume":"21","author":"SM Hashemi","year":"2014","unstructured":"Hashemi SM, Fischer K, Moons KGM, van den Berg HM. Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A. Haemophilia. 2014;21:227\u201333. https:\/\/doi.org\/10.1111\/hae.12566.","journal-title":"Haemophilia"},{"key":"1536_CR18","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1182\/bloodadvances.2023011388","volume":"8","author":"S Hassan","year":"2024","unstructured":"Hassan S, Baselli G, Mollica L, Rossi RL, Chand H, El-Beshlawy A, et al. Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort. Blood Adv. 2024;8:2880\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023011388.","journal-title":"Blood Adv"},{"key":"1536_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14325","author":"S Hassan","year":"2021","unstructured":"Hassan S, Palla R, Valsecchi C, Garagiola I, El\u2010Beshlawy A, Elalfy M, et al. Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia. 2021. https:\/\/doi.org\/10.1111\/hae.14325.","journal-title":"Haemophilia"},{"key":"1536_CR20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood-2002-05-1369","volume":"101","author":"M Jacquemin","year":"2003","unstructured":"Jacquemin M, Vantomme V, Buhot C, Lavend\u2019homme R, Burny W, Demotte N, et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild\/moderate hemophilia A. Blood. 2003;101:1351\u20138. https:\/\/doi.org\/10.1182\/blood-2002-05-1369.","journal-title":"Blood"},{"key":"1536_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1538-7836.2011.04202.x","volume":"9","author":"EA James","year":"2011","unstructured":"James EA, van Haren SD, Ettinger RA, Fijnvandraat K, Liberman JA, Kwok WW, et al. T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost. 2011;9:689\u201399. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04202.x.","journal-title":"J Thromb Haemost"},{"key":"1536_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/rth2.12335","volume":"4","author":"LL Jardim","year":"2020","unstructured":"Jardim LL, Chaves DG, Rezende SM. Development of inhibitors in hemophilia A: an illustrated review. Res Pract Thromb Haemost. 2020;4:752\u201360. https:\/\/doi.org\/10.1002\/rth2.12335.","journal-title":"Res Pract Thromb Haemost"},{"key":"1536_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ajhg.2017.12.010","volume":"102","author":"Y Jourdy","year":"2018","unstructured":"Jourdy Y, Janin A, Fretigny M, Lienhart A, N\u00e9grier C, Bozon D, et al. Reccurrent F8 intronic deletion found in mild hemophilia a causes Alu Exonization. Am J Hum Genet. 2018;102:199\u2013206. https:\/\/doi.org\/10.1016\/j.ajhg.2017.12.010.","journal-title":"Am J Hum Genet"},{"key":"1536_CR24","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide-mhc class i interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199:3360\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1700893.","journal-title":"J Immunol"},{"key":"1536_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","volume":"15","author":"KM Keeling","year":"2014","unstructured":"Keeling KM, Xue X, Gunn G, Bedwell DM. Therapeutics based on stop codon readthrough. Annu Rev Genomics Hum Genet. 2014;15:371\u201394. https:\/\/doi.org\/10.1146\/annurev-genom-091212-153527.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"1536_CR26","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1182\/bloodadvances.2018019323","volume":"2","author":"CL Kempton","year":"2018","unstructured":"Kempton CL, Payne AB. HLA-DRB1\u2013factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study. Blood Adv. 2018;2:1750\u20135. https:\/\/doi.org\/10.1182\/bloodadvances.2018019323.","journal-title":"Blood Adv"},{"key":"1536_CR27","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1182\/bloodadvances.2025015799","volume":"9","author":"E Li","year":"2025","unstructured":"Li E, Li Z, Wang J, Wu H, Xue Y, Lou C, et al. Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX. Blood Adv. 2025;9:3967\u201378. https:\/\/doi.org\/10.1182\/bloodadvances.2025015799.","journal-title":"Blood Adv"},{"key":"1536_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/17474086.2020.1739518","volume":"13","author":"D Lillicrap","year":"2020","unstructured":"Lillicrap D, Fijnvandraat K, Young G, Mancuso ME. Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Rev Hematol. 2020;13:313\u201321. https:\/\/doi.org\/10.1080\/17474086.2020.1739518.","journal-title":"Expert Rev Hematol"},{"key":"1536_CR29","doi-asserted-by":"publisher","first-page":"9449","DOI":"10.3390\/ijms21249449","volume":"21","author":"S Lombardi","year":"2020","unstructured":"Lombardi S, Testa MF, Pinotti M, Branchini A. Molecular insights into determinants of translational readthrough and implications for nonsense suppression approaches. Int J Mol Sci. 2020;21:9449. https:\/\/doi.org\/10.3390\/ijms21249449.","journal-title":"Int J Mol Sci"},{"key":"1536_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1055\/s-0044-1791778","volume":"51","author":"ME Mancuso","year":"2025","unstructured":"Mancuso ME. Factor replacement treatment for hemophilia A: achievements and perspectives. Semin Thromb Hemost. 2025;51:18\u201322. https:\/\/doi.org\/10.1055\/s-0044-1791778.","journal-title":"Semin Thromb Hemost"},{"issue":"25","key":"1536_CR31","doi-asserted-by":"publisher","first-page":"00925","DOI":"10.1016\/j.jtha.2025.12.014","volume":"S1538\u20137836","author":"E Manderstedt","year":"2026","unstructured":"Manderstedt E, Lind-Halld\u00e9n C, Halld\u00e9n C, Astermark J, Hemophilia Inhibitor Genetics Study Cohort. Non-carrier mothers of hemophilia A patients with Inv22 inversions often have other rearrangements. J Thromb Haemost. 2026;S1538\u20137836(25):00925. https:\/\/doi.org\/10.1016\/j.jtha.2025.12.014.","journal-title":"J Thromb Haemost"},{"key":"1536_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","volume":"21","author":"PM Mannucci","year":"2023","unstructured":"Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. J Thromb Haemost. 2023;21:403\u201312. https:\/\/doi.org\/10.1016\/j.jtha.2022.12.029.","journal-title":"J Thromb Haemost"},{"key":"1536_CR33","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1017\/s1355838200000716","volume":"6","author":"M Manuvakhova","year":"2000","unstructured":"Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA. 2000;6:1044\u201355. https:\/\/doi.org\/10.1017\/s1355838200000716.","journal-title":"RNA"},{"key":"1536_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/biomedicines14020343","volume":"14","author":"A Matucci","year":"2026","unstructured":"Matucci A, Feriozzi S, Biagini E, Mangeri M, Accinno M, Diomiaiuti M, et al. Immunogenicity in fabry disease: current issues, coping strategies, and future directions. Biomedicines. 2026;14:343. https:\/\/doi.org\/10.3390\/biomedicines14020343.","journal-title":"Biomedicines"},{"key":"1536_CR35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/hae.13947","volume":"26","author":"JH McVey","year":"2020","unstructured":"McVey JH, Rallapalli PM, Kemball-Cook G, Hampshire DJ, Giansily-Blaizot M, Gomez K, et al. The European Association for Haemophilia and Allied Disorders (EAHAD) Coagulation Factor Variant Databases: Important resources for haemostasis clinicians and researchers. Haemophilia. 2020;26:306\u201313. https:\/\/doi.org\/10.1111\/hae.13947.","journal-title":"Haemophilia"},{"key":"1536_CR36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286204","author":"M Miranda","year":"2024","unstructured":"Miranda M, Hansen BE, Wehbi B, Porcheddu V, Van Alphen FPJ, Kaijen P, et al. FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4. Haematologica. 2024. https:\/\/doi.org\/10.3324\/haematol.2024.286204.","journal-title":"Haematologica"},{"key":"1536_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-296","author":"M Nielsen","year":"2009","unstructured":"Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 2009. https:\/\/doi.org\/10.1186\/1471-2105-10-296.","journal-title":"BMC Bioinformatics"},{"key":"1536_CR38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/hae.12276","volume":"20","author":"AD Pashov","year":"2013","unstructured":"Pashov AD, Calvez T, Gilardin L, Maill\u00e8re B, Repess\u00e9 Y, Oldenburg J, et al. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia. 2013;20:176\u201384. https:\/\/doi.org\/10.1111\/hae.12276.","journal-title":"Haemophilia"},{"key":"1536_CR39","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1182\/bloodadvances.2022007267","volume":"7","author":"H Paul","year":"2023","unstructured":"Paul H, Berg V, Gangadharan B, Bowen J, LeBeau P, Blatn\u00fd J, et al. Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication. Blood Adv. 2023;7:1831\u201348. https:\/\/doi.org\/10.1182\/bloodadvances.2022007267.","journal-title":"Blood Adv"},{"key":"1536_CR40","doi-asserted-by":"publisher","first-page":"E2382","DOI":"10.1002\/humu.22247","volume":"34","author":"AB Payne","year":"2013","unstructured":"Payne AB, Miller CH, Kelly FM, Michael Soucie J, Craig Hooper W. The CDC Hemophilia A Mutation Project (CHAMP) mutation list: a new online resource. Hum Mutat. 2013;34:E2382-2391. https:\/\/doi.org\/10.1002\/humu.22247.","journal-title":"Hum Mutat"},{"key":"1536_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","volume":"388","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388:187\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(15)01123-X.","journal-title":"Lancet"},{"key":"1536_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/jth.13888","volume":"16","author":"F Peyvandi","year":"2018","unstructured":"Peyvandi F, Cannav\u00f2 A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR, et al. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018;16:39\u201343. https:\/\/doi.org\/10.1111\/jth.13888.","journal-title":"J Thromb Haemost"},{"key":"1536_CR43","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/humu.22120","volume":"33","author":"M Pinotti","year":"2012","unstructured":"Pinotti M, Caruso P, Canella A, Campioni M, Tagariello G, Castaman G, et al. Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations. Hum Mutat. 2012;33:1373\u20136. https:\/\/doi.org\/10.1002\/humu.22120.","journal-title":"Hum Mutat"},{"key":"1536_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-genet-111212-133424","volume":"47","author":"MW-L Popp","year":"2013","unstructured":"Popp MW-L, Maquat LE. Organizing principles of mammalian nonsense-mediated mRNA decay. Annu Rev Genet. 2013;47:139\u201365. https:\/\/doi.org\/10.1146\/annurev-genet-111212-133424.","journal-title":"Annu Rev Genet"},{"key":"1536_CR45","doi-asserted-by":"publisher","first-page":"e16331","DOI":"10.1016\/j.heliyon.2023.e16331","volume":"9","author":"A Rawal","year":"2023","unstructured":"Rawal A, Kidchob C, Ou J, Yogurtcu ON, Yang H, Sauna ZE. A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII. Heliyon. 2023;9:e16331. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16331.","journal-title":"Heliyon"},{"key":"1536_CR46","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48:W449\u201354. https:\/\/doi.org\/10.1093\/nar\/gkaa379.","journal-title":"Nucleic Acids Res"},{"key":"1536_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/3-540-28217-3_1","volume":"155","author":"S Rospert","year":"2005","unstructured":"Rospert S, Rakwalska M, Dubaqui\u00e9 Y. Polypeptide chain termination and stop codon readthrough on eukaryotic ribosomes. Rev Physiol Biochem Pharmacol. 2005;155:1\u201330. https:\/\/doi.org\/10.1007\/3-540-28217-3_1.","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"1536_CR48","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1073\/pnas.1424127112","volume":"112","author":"B Roy","year":"2015","unstructured":"Roy B, Leszyk JD, Mangus DA, Jacobson A. Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3. Proc Natl Acad Sci U S A. 2015;112:3038\u201343. https:\/\/doi.org\/10.1073\/pnas.1424127112.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1536_CR49","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1055\/s-0038-1649954","volume":"74","author":"R Schwaab","year":"1995","unstructured":"Schwaab R, Brackmann H-H, Meyer C, Seehafer J, Kirchgesser M, Haack A, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74:1402\u20136. https:\/\/doi.org\/10.1055\/s-0038-1649954.","journal-title":"Thromb Haemost"},{"key":"1536_CR50","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/bloodadvances.2021005745","volume":"6","author":"H Schweiger","year":"2022","unstructured":"Schweiger H, Rejt\u0151 J, Hofbauer CJ, Berg V, Allacher P, Zwiauer K, et al. Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors. Blood Adv. 2022;6:946\u201358. https:\/\/doi.org\/10.1182\/bloodadvances.2021005745.","journal-title":"Blood Adv"},{"key":"1536_CR51","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bjh.13131","volume":"168","author":"AJ Shepherd","year":"2014","unstructured":"Shepherd AJ, Skelton S, Sansom CE, Gomez K, Moss DS, Hart DP. A large-scale computational study of inhibitor risk in non-severe haemophilia A. Br J Haematol. 2014;168:413\u201320. https:\/\/doi.org\/10.1111\/bjh.13131.","journal-title":"Br J Haematol"},{"key":"1536_CR52","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288250","author":"H Singer","year":"2025","unstructured":"Singer H, Chawla P, Czogalla-Nitsche KJ, Engels P, Forin F, Sylvester M, et al. Divergent processing of FVIII light chain variants: secretory potential versus proteasomal retention. Haematologica. 2025. https:\/\/doi.org\/10.3324\/haematol.2025.288250.","journal-title":"Haematologica"},{"key":"1536_CR53","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/jth.13961","volume":"16","author":"S Spena","year":"2018","unstructured":"Spena S, Garagiola I, Cannav\u00f2 A, Mortarino M, Mannucci PM, Rosendaal FR, et al. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. J Thromb Haemost. 2018;16:778\u201390. https:\/\/doi.org\/10.1111\/jth.13961.","journal-title":"J Thromb Haemost"},{"key":"1536_CR54","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1111\/j.1538-7836.2008.03187.x","volume":"6","author":"PC ter Avest","year":"2008","unstructured":"ter Avest PC, Fischer K, Mancuso ME, Santagostino E, Yuste VJ, van den Berg HM, et al. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost. 2008;6:2048\u201354. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.03187.x.","journal-title":"J Thromb Haemost"},{"key":"1536_CR55","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3324\/haematol.2022.281279","volume":"108","author":"MF Testa","year":"2023","unstructured":"Testa MF, Lombardi S, Bernardi F, Ferrarese M, Belvini D, Radossi P, et al. Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association. Haematologica. 2023;108:472\u201382. https:\/\/doi.org\/10.3324\/haematol.2022.281279.","journal-title":"Haematologica"},{"key":"1536_CR56","doi-asserted-by":"publisher","first-page":"100650","DOI":"10.1016\/j.ymgmr.2020.100650","volume":"25","author":"T Tsukimura","year":"2020","unstructured":"Tsukimura T, Tayama Y, Shiga T, Hirai K, Togawa T, Sakuraba H. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy. Mol Genet Metab Rep. 2020;25:100650. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100650.","journal-title":"Mol Genet Metab Rep"},{"key":"1536_CR57","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jtha.2024.12.039","volume":"23","author":"LE van Stam","year":"2025","unstructured":"van Stam LE, Lacroix-Desmazes S, Fijnvandraat K, Gouw SC. Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature. J Thromb Haemost. 2025;23:1169\u201384. https:\/\/doi.org\/10.1016\/j.jtha.2024.12.039.","journal-title":"J Thromb Haemost"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01536-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01536-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01536-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:57:47Z","timestamp":1789430267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01536-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01536-y","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"144"}}